A novel anti-TB compound extracted from the soil of Antarctica, has shown promising activity against drug resistant TB. FNDR is a patent holder along with National Centre for Polar and Ocean Research, Ministry of Earth Sciences, Government of India. Development for TB is funded by BIRAC. It is also known as NF1001. FNDR20364 has also shown excellent in vitro activity against multiple drug sensitive and drug resistant NTMs and its development for NTMs is funded by the Cystic Fibrosis Foundation (CFF), USA. FNDR20364 also works against drug resistant Gram-postive bacteria.